Fig. 5.

CGRP is involved in the pathophysiology of migraine. CGRP is released from trigeminal afferent nerve fibers during a migraine and causes vasodilatation and neurogenic inflammation. Raised levels of CGRP are observed both peripherally and centrally in migraine patients. CGRP antibodies and antagonists are thought to reduce migraine by reducing these CGRP levels or through blocking the actions of CGRP. CGRP antibodies are peripherally restricted, whereas CGRP antagonists may have central actions.